Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters by Wang, Hai-bo et al.
Clin Chem Lab Med 2009;47(7):811–817  2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2009.186 2009/5
Article in press - uncorrected proof
Expression of RhoA and RhoC in colorectal carcinoma
and its relations with clinicopathological parameters
Hai-bo Wang1, Xiang-ping Liu2,*, Jun Liang3,
Kun Yang2, Ai-hua Sui2 and Yan-jun Liu1
1 Department of General Surgery, Affiliated Hospital
of Qingdao University Medical College, Qingdao,
China
2 Central Laboratory of Molecular Biology, Affiliated
Hospital of Qingdao University Medical College,
Qingdao, China
3 Department of Oncology, Affiliated Hospital of
Qingdao University Medical College, Qingdao, China
Abstract
Background: Ras homologous (Rho) family GTPases
play a pivotal role in the regulation of numerous
cellular functions associated with malignant transfor-
mation and metastasis. To evaluate the role of these
GTPases in colorectal cancer, the mRNA expression
levels in matched sets of tumor and non-tumor tis-
sues from surgical specimens were analyzed. The
relationship between the mRNA levels in tumor tis-
sues to the clinicopathological features was also
assessed.
Methods: A total of 68 patients with colorectal carci-
noma were recruited and the levels of RhoA and RhoC
mRNA transcripts in cancer, paratumoral and normal
tissues were characterized by quantitative real-time
polymerase chain reaction (QRT-PCR). Their correla-
tion to clinical histopathological parameters was
analyzed.
Results: The levels of RhoA and RhoC mRNA tran-
scripts in carcinoma tissues were significantly higher
than those in the matched paratumor and normal tis-
sues from the same patient (p-0.05). The expression
levels of both genes were significantly correlated with
metastasis of cancer cells to lymph nodes and liver
(p-0.05). The levels of RhoA expression were signif-
icantly correlated with the histopathological degree of
cancer, while the expression of RhoC was correlated
with the extent of local invasion to intestine.
Conclusions: This is the first study with QRT-PCR to
examine the expressions of RhoA and RhoC genes in
colorectal carcinoma of Chinese patients. The signifi-
cantly up-regulated RhoA and RhoC expressions
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suggest that they may contribute to the initiation,
development, invasion and metastasis of colorectal
carcinoma in Chinese patients.
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Keywords: colorectal carcinoma; gene expression;
real-time polymerase chain reaction (RT-PCR); RhoA;
RhoC.
Introduction
Colorectal carcinoma is one of the most common
malignancies with an increasing annual incidence (1).
Colorectal carcinoma is usually accompanied by local
invasion and distant metastasis, which are the main
causative factors for cancer-related death (2). The ini-
tiation, development, local invasion and distal metas-
tasis are closely regulated by multiple genes, whose
expression are determined by internal or external fac-
tors. Therefore, elucidation of these factors and the
pattern of their expression may help to understand
the progression of colorectal carcinoma, and help pre-
dict the clinical outcome of patients with colorectal
carcinoma.
The Ras homologous (Rho) sub-family of low-
molecular-weight GTP-binding proteins contains Rho
(e.g., RhoA, B, C), Rac and Cdc42 proteins (3). These
molecules are involved in the regulation of a variety
of cellular processes, such as the organization of the
microfilament network, cell–cell contact and malig-
nant transformation (4). Furthermore, they play
important roles in intracellular signal transduction,
regulate cell proliferation, apoptosis, adhesion and
motility (5). Abnormal expression and activation of
both RhoA and RhoC have been demonstrated to
correlate with the development and metastasis of
malignant carcinoma (3). Increased expression of
RhoC has been found to correlate with poor outcome
in Caucasians with colorectal carcinoma, and may
also be used as a prognostic marker in these patients
(6). Increased expression of RhoA has been observed
in Asians with colorectal carcinoma (7). However, lit-
tle is known about whether the expression of those
oncogenes is altered in Chinese patients with colo-
rectal carcinoma, and how this expression is correlat-
ed with the clinicopathological characteristics of
Chinese patients with colorectal carcinoma.
The quantitative real-time polymerase chain reac-
tion (QRT-PCR) is a new fluorescence-based technol-
ogy that can be used to amplify and simultaneously
quantify targeted DNA molecules. Together with
reverse transcription, this technology can be
employed to quantitatively measure mRNA tran-
scripts of one gene at a particular time in certain cells
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or tissues. In this study, we employed the QRT-PCR
to examine the expressions of RhoA and RhoC genes
in colorectal carcinoma tissue from Chinese patients,
and analyze the relationship between its expression
and various clinicopathological parameters. Our data
demonstrated high levels of RhoA and RhoC mRNA
transcripts in colorectal carcinoma from Chinese
patients, which may contribute to the initiation, pro-
gression and metastasis of colorectal carcinoma.
Materials and methods
Subjects and sample collection
A total of 68 patients with colorectal carcinoma who under-
went surgery in the Department of General Surgery, the
Affiliated Hospital of Qingdao University Medical College
between January 2007 and April 2008, were recruited for this
study after informed consent was obtained. There were 38
males and 30 females, with an average age of 61.5 years
(range 36–80 years). For the 68 cases, there were 31 with
colon carcinoma and 37 with rectal carcinoma. Diagnoses
were confirmed by pathological examinations. Prior to sur-
gery, none of the patients received chemotherapy or radio-
therapy. At surgery, tumor tissue, paratumor tissue (3–5 cm
from the border of the tumor) and normal tissue ()5 cm
from the border of the tumor) were resected. Based on the
histopathological classifications, six out of 68 cases were
highly differentiated, 45 moderately differentiated and 17
low differentiated adenocarcinomas. According to the TNM
staging for colorectal carcinoma (UICC, 2006), there were six
cases at T1, 18 at T2, 35 at T3 and nine at T4. Twenty-four
patients had metastasis to lymph nodes, and 11 to the liver,
including two with concomitant metastasis to the liver and
lung. The tissues were immediately frozen in liquid nitrogen
and stored at –708C until use.
Primer design and synthesis
The specific primers used for amplifying the targeted gene
fragments with QRT-PCR were designed using the Primer
Express software (Applied Biosystems, Foster City, CA,
USA), based on the sequences of these genes, and analyzed
using the basic local alignment search tool (BLAST) to deter-
mine their specificity. The primers for the human RhoA gene
were: sense 5’-CGGGAGCTAGCCAAGATGAAG-3’, antisense
5’-CCTTGCAGAGCAGCTCTCGTA-3’, fluorescent probe 5’-
FAM-AGAGATATGGCAAACAGGATTGGCG-TAMRA-3’, and
the amplicon size was 158 base pairs (bp). The primers for
the human RhoC gene were: sense 5’-CCTCATGTGCTTCTC-
CATCGA-3’, antisense 5’-CTCGTCTTGCCTCAGGTCCTT-3’,
fluorescent probe 5’-FAM-TCTGCCCCAACGTGCCCATCAT-
TAMRA-3’, and the amplicon size was 136 bp. GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase) was used as the
internal control with the specific primers: sense 5’-CTTAG-
CACCCCTGGCCAAG-3’, antisense 5’-GATGTTCTGGAGAGC-
CCCG-3’, fluorescent probe 5’-FAM-CATGCCATCACTGCCA-
CCCAGAAGA-TAMRA-3’, and the amplicon size was 150 bp.
The primers and fluorescent probes were synthesized by
Shanghai Sangon Biological Engineering Technology &
Services Co., Ltd. (Shanghai, China).
RNA and cDNA preparation and QRT-PCR
Total RNA was extracted from tissue samples using Trizol
(Invitrogen, Gaithersburg, MD, USA) and reverse transcript-
ed into cDNA using the PrimeScript RT-PCR kit (TaKaRa Bio
Inc, Shiga, Japan) according to the manufacturer’s instruc-
tions. To test the specificity of the primers, different sets of
primers were tested for amplifying the targeted DNA from
the cDNA by polymerase chain reaction (PCR). The reactions
were subjected to an initial denaturation at 958C for 10 s,
followed by 40 cycles of denaturation at 958C for 5 s, and
annealing and extension at 608C for 45 s. The PCR products
were analyzed on a 2% agarose gel and by sequencing
(Shanghai Sangon, Shanghai, China).
The levels of RhoA, RhoC and control GAPDH mRNA tran-
scripts were determined with the QRT-PCR in an ABI7500
real-time thermal cycler (Applied Biosystems, Foster City,
CA, USA). The PCR reactions in duplicate were subjected to
initial denaturation at 958C for 10 s, followed by 40 cycles of
denaturation at 958C for 5 s, and annealing and extension at
608C for 45 s. The value of the threshold cycle (CT) for
each reaction was recorded. The levels of RhoA and RhoC
mRNA transcripts relative to GAPDH were expressed
as the DCT(CTTarget–CTGAPDH) and DDCT, where DDCTs
(CTTarget–CTGAPDH)cancer tissue–(CTTarget–CTGAPDH)normal tissue (8).
Amplification efficacy of the target and internal control
genes were determined, and only the slope value of log tar-
get gene copies vs. DCT-0.1 was further quantified using
the 2–DDCT method. Amplification efficiencies of RhoA, RhoC
and GAPDH (internal control) genes were examined by QRT-
PCR using serial 2-fold dilutions of reverse-transcribed
cDNA. Assays were done in duplicate, and each experiment
was repeated 2 times. Data were expressed as mean"SEM.
Statistical analysis
Data were expressed as mean"SD. Differences between
groups were analyzed using Students t-test or ANOVA with
SPSS software (Ver. 11.5, SPSS Inc., Chicago, IL, USA). Cor-
relation between covariates were determined using Pearson




To determine the levels of RhoA and RhoC mRNA
transcripts, total RNA was extracted from individual
samples and the purity of these RNA samples deter-
mined by the ratio of optical density (OD260/OD280).
The ratio was between 1.8 and 2.0, suggesting high
purity of RNA. Following reverse transcription into
cDNA, the target gene fragments of RhoA, RhoC and
GAPDH were amplified by PCR (Figure 1). As expect-
ed, individual DNA products were observed with
RhoA (158 bp), RhoC (136 bp) and GAPDH (150 bp),
respectively (Figure 1), suggesting high-specificity of
the primers. Further sequence analysis revealed that
the PCR products were RhoA, RhoC and GAPDH DNA
fragments (Figure 2). These preliminary results pro-
vided a reasonable basis for quantitative characteri-
zation of RhoA, RhoC and GAPDH mRNA transcripts
in the tissue samples.
Amplification efficiency
Amplification curves of serially diluted cDNA samples
exhibited a standard S shape, suggesting a good
amplification efficiency and a linear relationship. For
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Figure 1 Gel electrophoresis of PCR products.
M, size marker; 1, RhoA; 2, RhoC; 3, GAPDH.
Figure 2 Sequencing histograms of PCR products for RhoA, RhoC and GAPDH.
the RhoA and RhoC genes, the log value of each
cDNA dilution was plotted vs. DCT, showing a slope
of 0.0797 and 0.0864, respectively (Figures 3 and 4).
This indicated that both target genes had amplifica-
tion efficiencies similar to the internal control genes
(GAPDH), justifying application of the 2–DDCT method
for relative quantification (9).
High levels of RhoA and RhoC mRNA transcripts
in colorectal carcinoma tissues
We first examined the expression of RhoA, RhoC and
GAPDH in tissue samples obtained from 68 patients
with colorectal carcinoma (Figure 5). Data analysis
showed the values of RhoA and RhoC mRNA in tumor
samples to be significantly higher compared with that
found in paratumor or normal tissue (p-0.05). The
relative levels of RhoA and RhoC mRNA in tumor
samples compared with normal samples were 4.53
(3.81–5.39) and 3.83 (3.11–4.73), respectively. These
results demonstrated significantly higher expression
of RhoA and RhoC mRNA in tumor samples (p-0.05).
However, there was no significant difference between
paratumor and normal tissue samples (p)0.05)
(Table 1). The high levels of RhoA and RhoC mRNA
transcripts shown in colorectal carcinoma tissues
suggest that both RhoA and RhoC expression may
contribute to the tumorigenesis of colorectal carci-
noma in Chinese patients.
Correlation of RhoA and RhoC gene expressions
to clinical histopathological features of colorectal
carcinoma
We analyzed the relationship between the levels of
RhoA and RhoC gene expression. The levels of RhoA
mRNA transcripts were correlated with that of RhoC
mRNA expression in the colorectal tumor samples
(rs0.847, p-0.01). Further analysis of the relationship
between the levels of RhoA or RhoC expression and
various clinical histopathological features revealed
that the expression of both genes was significantly
correlated with the presence of metastasis to lymph
nodes or liver (p-0.05), but was independent of
patient’s age and gender. In addition, the level of
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Figure 3 Plot of log input amount vs. DCT(RhoA–GAPDH).
Figure 4 Plot of log input amount vs. DCT(RhoC–GAPDH).
Figure 5 Amplification curve of GAPDH, RhoA and RhoC.
RhoA expression was correlated with histopathologi-
cal degree of cancer, while RhoC was correlated with
the extent of local invasion to the intestine (p-0.05)
(Table 2).
Discussion
The Rho family of GTPase functions as a molecular
switch within cells. In response to intra- and extra-
cellular signals, it cycles between an active GTP-
bound form and an inactive GDP-bound form. The
Rho family not only regulates the organization of the
actin filament system but also modulates cell motility,
proliferation, apoptosis, cell cycle progression, and
invasion and metastasis of malignant tumor cells (10).
Small GTPase of the Rho family plays an important
role in eukaryotic signal transduction, which primarily
affects the organization of the cytoskeleton involved
with movement. Rho-associated protein kinase
(ROCK) is a key downstream effector of Rho proteins
(11, 12). Recent data have implicated that the Rho/
ROCK pathway plays an important role in the invasion
and metastasis of cancer cells (13–15).
RhoA has been shown to regulate the activities of
multiple transcription factors. The majority of these
factors have been implicated in cancer progression
(16) by modulating cancer cell adhesion, contraction,
movement, release of cellular adhesion, degradation
of extra-cellular matrix, and invasion into blood or
lymph vessels (17–19). In gastric cancer, high levels
of RhoA expression were observed in tumors at more
advanced stages, histologically diffuse, aggressive
metastasis into lymph nodes and poorer survival (20).
RhoA itself also has transformation activity, often
interacting with Ras gene mutations, especially K-ras,
which is a common event in colorectal carcinoma, to
promote cellular transformation (21).
RhoC also contributes to tumor development,
especially invasion and metastasis of cancer cells. Its
functions are likely mediated by the following mech-
anisms (22, 23): 1) disrupting cellular polarity,
2) depriving cells of adherent junctions, 3) promoting
cellular motility and remodeling extra-cellular matrix
to enhance the local invasiveness of cancer cells,
4) up-regulating the expression of factors involved in
angiogenesis to promote the intravasation of tumor
cells into blood vessels. RhoC has been considered a
marker for early metastasis of cancer (24). Clark and
colleagues identified high RhoC gene expression in
highly metastatic melanoma cells by microarray.
They were also the first to demonstrate the causative
role of RhoC expression in tumor cell invasion, pro-
posing the involvement of RhoC in tumor invasion
and metastasis (25). In prostate cancer, over-expres-
sion of RhoC enhances cellular invasion, and its
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Table 1 Relative expression of RhoA and RhoC genes in different tissues.
Tissue type Sample RhoA RhoC
number (n)
DDCT Relative to normala DDCT Relative to normala
Normal 68 0"0.2014 1 (0.87–1.15) 0"0.2512 1 (0.84–1.19)
Paratumor 68 –0.1551"0.1711 1.11 (0.98–1.25) –0.0955"0.2437 1.07 (0.90–1.27)
Tumor 68 –2.1799"0.2509 4.53 (3.81–5.39) –1.9387"0.3019 3.83 (3.11–4.73)
aData are expressed as the mean 2–DDCT (range).
Table 2 Correlation between RhoA and RhoC DDCT values and clinical histopathological parameters.
Pathological features Case DDCT (RhoA) p-Value DDCT (RhoC) p-Value
number
Gender
Male 38 –2.255"0.3621 )0.05 –1.9767"0.2611 )0.05
Female 30 –2.105"0.2766 –1.9007"0.3562
Site of tumor
Colon 31 –2.1675"0.2577 )0.05 –1.8614"0.2763 )0.05
Rectum 37 –2.1923"0.2132 –2.0160"0.3269
Histological subtypes
High and moderate differentiation 51 –2.0875"0.1734 -0.05 –1.9266"0.3326 )0.05
Low differentiation 17 –2.3602"0.2877 –1.9913"0.3125
Extent of intestinal invasion
T1qT2 24 –2.1405"0.2847 )0.05 –1.7005"0.2566 -0.05
T3qT4 44 –2.2036"0.1964 –2.0673"0.2137
Lymph node metastasis
Positive 24 –2.3503"0.1926 -0.05 –2.1503"0.1344 -0.05
Negative 44 –2.0732"0.2533 –1.8362"0.2581
Liver metastasis
Positive 11 –2.4106"0.0810 -0.05 –2.2662"0.1050 -0.05
Negative 55 –2.1422"0.2198 –1.9405"0.1911
expression level correlates directly with the invasive-
ness of prostate cancer cells (26). In liver carcinoma,
retroviral transduction of RhoC siRNA inhibits cellular
motility (27).
Fluorescence-based QRT-PCR is a fast and accurate
technique, and can be used for quantifying the levels
of mRNA transcripts. It has been widely used in dif-
ferent fields of molecular biology. In this study, we
characterized the relative levels of RhoA and RhoC
mRNA transcripts in tissues by QRT-PCR. In theory,
relative quantification requires comparison of the
quantity of mRNA between samples derived from the
same number of cells. This is very difficult in practice
given the difficulties in obtaining the same number of
cells from different samples. In addition, there is var-
iability in RNA extraction and PCR amplification. We
standardized the mRNA levels of our target genes
against GAPDH, which is an internal housekeeping
gene. Then we compared mRNA levels between dif-
ferent samples, improving the validity of the result
(28, 29).
Colorectal carcinoma is a common malignancy.
Local invasion and metastasis is a key factor compro-
mising the efficacy of treatment. However, the under-
lying molecular and cellular mechanisms are poorly
understood. In this study, we found that the levels of
RhoA and RhoC mRNA transcripts in tumor tissue
was significantly higher than that found in the corre-
sponding paratumor and normal tissues. These
results suggest involvement of these two genes in the
onset and development of colorectal carcinoma. In
addition, expression of both RhoA and RhoC in cancer
with metastasis to lymph nodes or liver was signifi-
cantly higher compared with cancer without metas-
tasis. This indicates that these two genes may
contribute to invasion and metastasis of colorectal
carcinoma. Specifically, the levels of RhoC expression
were significantly correlated with the extent of local
invasion to intestine, but not with the histopatholog-
ical degree of cancer. This strongly supports its func-
tion in tumor invasion and metastasis.
In gastric cancer, the adenovirus-mediated siRNA
against RhoA and RhoC down-regulates the expres-
sion of both genes and inhibits the proliferation and
invasiveness of cancer cells (30). Our study also iden-
tified positive correlation between mRNA levels of
these two genes (rs0.847, p-0.01). This suggests
cooperativity between these two genes in the initia-
tion and progression of cancer, especially invasion
and metastasis of colorectal carcinoma.
To our knowledge, this is the first study on the lev-
els of RhoA and RhoC mRNA transcripts in tissue
samples from Chinese patients with colorectal carci-
noma by QRT-PCR; similar studies have been per-
formed with other human tumors. Our results are
consistent with a previous study done by Faried et al.
that used essentially the same method in patients
with squamous cell carcinoma of the esophagus (31).
For quantitative methods, our TaqMan probes are
more precise than SYBR Green chemistry dyes used
by others. Another study used QRT-PCR and Western
blotting on tissue from 64 patients with liver cancer
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and found that the levels of RhoA mRNA transcripts
were correlated with protein levels, and higher
expression was correlated with tumor stage and
metastasis (32). In ovarian cancer, levels of RhoA and
RhoC mRNA and protein expression are up-regulated
in cancer tissue, as determined by QRT-PCR and
Western blot analysis (33). Shikada et al. examined
mRNA and protein levels of RhoC in 49 non-small cell
lung carcinoma. They found that mRNA levels were
correlated with protein levels, with both significantly
higher in tumor tissue, as compared with non-tumor
tissue (34).
We believe that levels of RhoA and RhoC mRNA
transcripts in colorectal carcinoma are correlated with
protein expression. Further study on RhoA and RhoC
expression in colorectal carcinoma may provide more
insight into the mechanisms underlying the action of
RhoA and RhoC in the development and metastasis
of colorectal carcinoma. Therefore, RhoA and RhoC
expression may be new markers of invasiveness of
colorectal carcinoma, and used as potential targets
for treatment.
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